The failure to detect drug-induced sensory loss in standard preclinical studies.

@article{Gauvin2015TheFT,
  title={The failure to detect drug-induced sensory loss in standard preclinical studies.},
  author={David V Gauvin and Matthew M. Abernathy and Rachel L. Tapp and Joshua D Yoder and Jill A Dalton and Theodore J. Baird},
  journal={Journal of pharmacological and toxicological methods},
  year={2015},
  volume={74},
  pages={53-74}
}
Over the years a number of drugs have been approved for human use with limited signs of toxicity noted during preclinical risk assessment study designs but then show adverse events in compliant patients taking the drugs as prescribed within the first few years on the market. Loss or impairments in sensory systems, such as hearing, vision, taste, and smell have been reported to the FDA or have been described in the literature appearing in peer-reviewed scientific journals within the first five… CONTINUE READING